Drug Search Results

LY2886721

Alternative Names: ly2886721
Latest Update: 2023-05-01
Latest Update Note: PubMed Publication

Product Description

Eli Lilly is developing LY2886721 as a treatment for Alzheimer's Disease. (Sourced from: https://investor.lilly.com/news-releases/news-release-details/lilly-voluntarily-terminates-phase-ii-study-ly2886721-beta)

Mechanisms of Action: BACE Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY2886721

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Alzheimer Disease

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
JapicCTI-121935	P2	Active	Alzheimer Disease	None

Recent News Events

Date	Type	Title
05/01/2023	PubMed	Human platelets release amyloid peptides β1-40 and β1-42 in response to haemostatic, immune, and hypoxic stimuli.
06/14/2022	PubMed	Beta-Site Amyloid Precursor Protein-Cleaving Enzyme Inhibition Partly Restores Sevoflurane-Induced Deficits on Synaptic Plasticity and Spine Loss.
03/09/2022	News Article	Skin Cancer Cells - As they Spread to the Brain - use an Alzheimer's Protein to Sabotage Immune Defenses
06/24/2021	PubMed	Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions